VIEW ALL RESEARCH-GROUP

Metabolism and cancer
Menendez’s Lab

DESCRIPTION

Unlocking the metabolic secrets of cancer: Our “Metabolism and Cancer” team studies how cellular metabolism drives cancer growth, drug resistance, and metastasis. We use cutting-edge laboratory experiments, computational tools and clinical trials to validate our discoveries in cancer patients.

MAIN RESEARCH LINES

  1. CANCER METABOLISM

    Metabolic inhibitors for cancer therapy

    • Metabolic mechanisms of tumorigenesis & drug resistance
    • Clinical development of anti-cancer metabolic drugs

    Mitochondria, senescence, and cancer

    • Mitochondria-based elimination of tumor-/metastasis-initiating cells
    • Metabolic therapy-induced senescence (MTIS)

    Metabolo-immunotherapy

    • Tumor cell-intrinsic immunometabolism 
    • Metabolic/dietary interventions and immunotherapy 
  2. BIOCOMPOUNDS
    • Natural biocompounds for cancer treatment
  3. COMPUTATIONAL BIOLOGY & CHEMISTRY
    • Mathematical modeling of cancer
    • Computational design of anti-cancer metabolic drugs

Javier A. Menendez

Group leaders

IP

Elisabet Cuyàs

Researchers

Established researcher (Miguel Servet)

Eila Serrano Hervás

Researchers

Postdoctoral researcher (INVESTIGO)

Sara Verdura

Researchers

Predoctoral researcher

Àngela Llop Hernández

Young investigators

Predoctoral researcher

Júlia López

Young investigators

Predoctoral researcher

Begoña Martín Castillo

Researchers

Established researcher (Unit of Clinical Research, ICO-Girona)

Eugeni López Bonet

Researchers

Established researcher (Hospital Trueta)

Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer

/in /by

Histol Histopathol. 2017 Jul;32(7):687-698. doi: 10.14670/HH-11-830. Epub 2016 Oct 7. ABSTRACT Fatty acid synthase (FASN) is a key lipogenic enzyme for de novo fatty acid biosynthesis and a druggable metabolic oncoprotein that is activated in most human cancers. We evaluated whether the HER2-driven lipogenic phenotype might represent a biomarker for sensitivity to pharmacological FASN blockade. […]

Ruth Lupu | Mayo Clinic, Rochester, USA

Pilar Blancafort | Harry Perkins Institute of Medical Research, Perth, Australia

Francesca Cutruzzolà | Sapienza University, Rome, Italy

Tomás Alarcón | ICREA-Centre de Recerca Matemàtica (CRM), Reus, Spain

Sílvia Osuna | ICREA-Institut de Química Computacional i Catàlisi (IQCC), Girona, Spain

Josep Sardanyés | Centre de Recerca Matemàtica (CRM), Barcelona, Spain

José Antonio Encinar | Universidad Miguel Hernández, Elche, Spain

Vicente Micol | Universidad Miguel Hernández, Elche, Spain

Antonio Segura-Carretero | Universidad de Granada, Granada, Spain

Jorge Joven | Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain

Carlos Peña Garay | Laboratorio Subterráneo de Canfranc (LSC), Spain

Menendez grup. Research group photo
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

Pujana’s LabPujana's LabGrup-Hematoligia-webSureda’s & Farre’s Lab